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Leukocytes	from	individuals	with	warts,	hypogammaglobulinemia,	infections,	and	myelokathexis	(WHIM)	
syndrome,	a	rare	immunodeficiency,	and	bearing	a	wild-type	CXCR4	ORF	(WHIMWT)	display	impaired	CXCR4	
internalization	and	desensitization	upon	exposure	to	CXCL12.	The	resulting	enhanced	CXCR4-dependent	
responses,	including	chemotaxis,	probably	impair	leukocyte	trafficking	and	account	for	the	immunohema-
tologic	clinical	manifestations	of	WHIM	syndrome.	We	provided	here	evidence	that	GPCR	kinase-3	(GRK3)	
specifically	regulates	CXCL12-promoted	internalization	and	desensitization	of	CXCR4.	GRK3-silenced	control	
cells	displayed	altered	CXCR4	attenuation	and	enhanced	chemotaxis,	as	did	WHIMWT	cells.	These	findings	
identified	GRK3	as	a	negative	regulator	of	CXCL12-induced	chemotaxis	and	as	a	candidate	responsible	for	
CXCR4	dysfunction	in	WHIMWT	leukocytes.	Consistent	with	this,	we	showed	that	GRK3	overexpression	in	
both	leukocytes	and	skin	fibroblasts	from	2	unrelated	WHIMWT	patients	restored	CXCL12-induced	internal-
ization	and	desensitization	of	CXCR4	and	normalized	chemotaxis.	Moreover,	we	found	in	cells	derived	from	
one	patient	a	profound	and	selective	decrease	in	GRK3	products	that	probably	resulted	from	defective	mRNA	
synthesis.	Taken	together,	these	results	have	revealed	a	pivotal	role	for	GRK3	in	regulating	CXCR4	attenuation	
and	have	provided	a	mechanistic	link	between	the	GRK3	pathway	and	the	CXCR4-related	WHIMWT	disorder.
Introduction
WHIM syndrome is a rare combined immunodeficiency disorder 
characterized by disseminated human papillomavirus–induced 
warts, hypogammaglobulinemia, recurrent bacterial infections, 
and myelokathexis, a form of neutropenia associated with abnor-
mal retention of mature neutrophils in the BM (1, 2). Many cases 
of WHIM syndrome have been linked to inherited heterozygous 
autosomal dominant mutations in the gene encoding CXCR4, a 
GPCR with a unique natural ligand, the chemokine stromal cell–
derived factor 1/CXCL12 (SDF-1/CXCL12) (3). Binding of agonist 
to GPCR allows this family of receptors to associate with and sig-
nal through heterotrimeric G proteins by way of the exchange of 
GDP with GTP on the G protein α subunit, followed by the dis-
sociation of the Gα from the Gβγ subunits, both of which exert 
regulation over various effectors (4).
WHIM-associated mutations of CXCR4 lead to the expression of 
a receptor that displays an enhanced and prolonged activation of 
G proteins (reviewed in ref. 5). We previously reported that, in leu-
kocytes from WHIM patients carrying a mutated CXCR4 receptor 
(CXCR41013), the increased G protein–dependent signaling is associ-
ated with the inability of CXCR4 to be uncoupled from G proteins 
(i.e., desensitized) and internalized in response to CXCL12 (6). In this 
genetic form of WHIM syndrome, impaired CXCR4 desensitization 
and internalization result from distal truncations of the receptor’s 
carboxyterminal tail (C-tail) that remove potential phosphorylation 
sites involved in this attenuation process. A similar pattern of CXCR4 
dysfunctions was observed in leukocytes from 2 unrelated sub-
jects with full clinical form of WHIM syndrome and carrying a WT 
(WHIMWT) CXCR4 ORF (6). This indicates that the altered CXCR4-
mediated signaling constitutes a common biologic trait of WHIM 
syndromes with different genetic causes. We thus hypothesized 
that WHIMWT patients display anomalies affecting a gene product 
involved in the regulation of the agonist-dependent phosphorylation 
and/or the coupling of CXCR4 to the endocytic pathway. Ultimately, 
the resulting enhanced CXCR4-dependent signaling likely impairs 
leukocyte trafficking and accounts for the peculiar association of 
lymphopenia and myelokathexis with WHIM syndrome.
Members of the GPCR kinase (GRK) and arrestin families are 
pivotal participants in the canonical pathways leading to ago-
nist-induced GPCR desensitization, a physiological feedback 
mechanism that rapidly uncouples the receptor from G proteins 
(7). GRKs phosphorylate Ser/Thr residues of intracellular loops 
and/or the C-tail of the agonist-activated receptor, a process that 
enhances the affinity of the receptor for the arrestins. The nonvi-
sual β-arrestin1 and -2 are reported to interact with intracellular 
domains of CXCR4 and to regulate receptor desensitization and 
internalization (8–11). Seven GRKs are known, and among them, 
the 4 widely expressed members (GRK2, -3, -5, and -6) are sup-
posed to regulate most GPCRs with overlapping receptor speci-
ficities (12, 13). Study of human diseases and genetically modified 
animals has recently revealed the physiological role of GRKs and 
pointed to some specificity of these kinases in regulating GPCR 
signaling (reviewed in ref. 14). However, to date, the GRKs respon-
sible for agonist-promoted phosphorylation, desensitization, and/
Nonstandard	abbreviations	used: ActD, actinomycin D; C-tail, carboxyterminal tail; 
GRK, GPCR kinase; IB, immunoblot; LB, lysis buffer; P3, patient 3; SCR, scrambled 
control; WHIM, warts, hypogammaglobulinemia, infections, and myelokathexis.
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or endocytosis of CXCR4 remain to be characterized, although 
some alterations of CXCR4 functions have been revealed in mice 
lacking Grk6 (10, 15). In this work, we identify GRK3 as a key reg-
ulator of CXCR4 attenuation, the impaired activity of which in 
WHIMWT cells accounts for the enhancement of CXCR4-mediated 
G protein–dependent responses.
Results
Selective CXCR4 dysfunctions in WHIMWT cells. We derived forearm 
skin fibroblasts from WHIMWT patient 3 (P3) and P4 and pro-
duced EBV-transformed B cell line from P4 (6), in order to set up 
cellular models to search for anomalies responsible for CXCR4 
dysfunctions. Membrane expression levels of endogenous CXCR4 
were barely detectable in all cell types (Figure 1A), as were other 
chemokine receptors, including CCR5, CCR7, CXCR2, CXCR5, 
and CXCR7, a newly identified receptor for CXCL12 (16) (data 
not shown). Following transduction, we analyzed the expression 
levels reached by CXCR4 at the membrane of either WHIMWT 
and control fibroblasts and B cells or the CXCR4-negative CHO 
cell and A0.01 T cell lines. Flow cytometry analysis indicated that 
expression levels of CXCR4 were comparable at the surface of all 
transduced cell types and in the same range as the endogenous 
ones detected in primary CD4+ T cells or Jurkat T cells (Figure 1B). 
In line with this, immunodetection of precipitated CXCR4 recep-
tors was achieved only in transduced control and WHIMWT EBV-B 
cells and increased in transduced PBL from a healthy subject. 
Immunoblot (IB) analysis revealed bands with a molecular weight 
close to that expected for CXCR4, as confirmed in A0.01 T cells 
expressing CXCR4 or its truncated C-tail counterpart CXCR41013 
(~39 and ~36 kDa, respectively) (Figure 1C).
Figure 1
Analysis of CXCR4 expression in WHIMWT-
derived cells. (A) Membrane expression levels 
of endogenous CXCR4 in fibroblasts and EBV-B 
cells from healthy (CTRL), P3, and P4 subjects 
(upper panels) were determined by flow cytometry 
using the PE-conjugated 12G5 anti-CXCR4 mAb 
(white histograms) and compared with control 
staining measured in the CXCR4-negative CHO 
and A0.01 cell lines (lower panels). Gray histo-
grams correspond to isotype control Ab. (B) Cell 
surface expression levels of endogenous CXCR4 
in CD4+ T cells from a healthy donor and the Jur-
kat T cell line (left panels) were compared with 
those of ectopically expressed CXCR4 following 
transduction of fibroblasts, EBV-B cells, CHO, and 
A0.01 cell lines (middle and right panels) with a 
WT or mutant (1013) CXCR4 cDNA. (C) Lysates 
of EBV-B cells from CTRL and P4 subjects, A0.01 
T cells, and PBLs from a healthy individual, either 
nontransduced (NT) or transduced with CXCR4WT 
(WT) or CXCR41013 (1013) cDNA, were incubated 
with the 12G5 anti-CXCR4 mAb precoated on 
γ-bind sepharose beads. Immunodetection of pre-
cipitated receptors using the SZ1567 anti-CXCR4 
Ab revealed bands with molecular weights close 
to those expected for CXCR4WT and CXCR41013 
(~39 and ~36 kDa, respectively). The thin vertical 
lines on the gel indicate that the lanes were run on 
the same gel but were noncontiguous. A repre-
sentative experiment out of 2 (C) or >5 (A and B) 
independent determinations is shown.
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Various chemokine receptors were ectopically expressed in control 
and WHIMWT fibroblasts and B cells to compare their functionality 
in response to their cognate ligand. Only WHIMWT B cells express-
ing CXCR4 displayed stronger migratory responses, and at all of the 
ligand concentrations, thus indicating a higher efficiency of CXCL12 
toward these cells (Figure 2A). Using CXCL12-triggered actin polym-
erization as an indicator of CXCR4-dependent G protein activation, 
we found that the enhanced chemotaxis of WHIMWT cells was asso-
ciated with a refractoriness of CXCR4 to be desensitized in response 
to CXCL12 (Figure 2B). In WHIMWT cells, CXCR4 was also resistant 
to CXCL12-induced internalization but remained sensitive to treat-
ment with the PKC inducer phorbol ester PMA (Figure 2C).
These findings show that WHIMWT fibroblasts and EBV-B cells 
display the CXCR4 dysfunctions reported in the related patient pri-
mary leukocytes (6) and that other chemokine receptors, including 
CXCR7, are fully sensitive to their cognate ligand. Genetic analy-
ses indicate the absence of mutation in the ORFs of CXCR4, 
CXCR7, and CXCL12 in lymphoid (leukocytes and EBV-B 
cells) and/or nonlymphoid (skin fibroblasts) cells derived 
from P3 and P4, thus ruling out the possibility that abnormal 
CXCL12-dependent responses result from anomalies target-
ing one of these genes. We thus hypothesized that impaired 
CXCR4 desensitization and internalization in WHIMWT cells 
rely on an abnormal gene product that directly or indirectly 
affects the agonist-dependent phosphorylation and/or the 
coupling of CXCR4 to the endocytic pathway.
β-arrestin–mediated CXCR4 internalization is preserved in 
WHIMWT cells. The cellular levels of β-arrestin2 determine the 
extent of CXCR4 desensitization and internalization (8–10). 
Accordingly, we found that β-arrestin2 expression in control 
fibroblasts significantly enhanced CXCL12-promoted inter-
nalization of CXCR4 (Figure 3A). Exogenous β-arrestin2 
also preserved the ability to modulate CXCR4 endocyto-
sis in fibroblasts and EBV-B cells (Figure 3A and data not shown, 
respectively) from WHIMWT patients, in contrast to overexpressed 
β-arrestin1 (Figure 3B). Thus, these data support a modest role for 
β-arrestin1 in the regulation of CXCL12-promoted internaliza-
tion of CXCR4 compared with that of β-arrestin2 (8, 9, 17). The 
question of whether impaired CXCR4 internalization in WHIMWT 
cells relies upon a change in β-arrestin levels was addressed by IB 
analysis using Abs recognizing β-arrestin2 and/or β-arrestin1 
(Supplemental Figure 1, A and B; supplemental material available 
online with this article; doi:10.1172/JCI33187DS1). We showed 
that steady-state levels of β-arrestin1 and β-arrestin2 proteins in 
WHIMWT fibroblasts were similar to those detected in control cells 
(Figure 3, A and B). These findings were confirmed in EBV-B cells 
and primary leukocytes from both patients (Supplemental Fig-
ure 1C) and extended to the mRNA level (data not shown). As the 
ORFs of β-arrestin1 and β-arrestin2 were found to be wild type in all 
Figure 2
Selective alteration of CXCR4 functioning in WHIMWT cells. (A) 
EBV-B cells from CTRL and P4 individuals were nucleopor-
ated with 5 μg of plasmids encoding CCR5, CCR7, CXCR2, 
CXCR4, or CXCR5 cDNA and assayed 15 h after transfection 
for chemotaxis using a Transwell system in response to the 
cognate chemokine (left section). Concentration-dependent 
migration of B cells expressing CXCR4 is shown in response 
to CXCL12 (right section). Results are expressed as a percent-
age of input B cells that migrated to the lower chamber. (B) 
Fibroblasts expressing CXCR4 (left panel) and B cells express-
ing either CXCR4 (middle panel) or CXCR5 (right panel) were 
tested for CXCL12- or CXCL13-triggered actin polymeriza-
tion using FITC-phalloidin as a probe for intracellular F-actin. 
Arrows indicate chemokine stimulation. The baseline level 
of unstimulated cells was set as 100% (dotted line). (C) Cell 
surface expression of distinct chemokine receptors in control 
(CTRL#1) and WHIMWT fibroblasts treated with 200 nM of 
the cognate agonist for 45 min at 37°C. Results indicate the 
amount of receptors that remains at the cell surface after incu-
bation with agonist. Receptor expression at the surface of cells 
incubated in medium alone was set as 100%. Following trans-
fection, expression levels of the different chemokine receptors 
were comparable at the surface of all unstimulated cell types as 
determined by flow cytometry (data not shown). Results repre-
sent the means ± SD of 3–5 independent experiments (A and 
C) or are representative of 3 independent determinations (B). 
*P < 0.05; **P < 0.005 compared with healthy subjects.
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WHIMWT cell types, our results indicate a normal synthesis, stabil-
ity, and translation of β-arrestin mRNAs in these cells. Altogether, 
these findings challenge the possibility that anomalies in β-arrestin 
account for the defective CXCR4 internalization in WHIMWT cells.
Moreover, the normal functioning of other chemokine recep-
tors also indicates that the endocytic pathway downstream of 
β-arrestin recruitment is preserved in WHIMWT cells. GRK-mediated 
phosphorylation of C-tail Ser/Thr residues of CXCR4 (18), and 
thus C-tail integrity, are required for β-arrestin binding and recep-
tor internalization (8, 19–21). Therefore, the impaired internaliza-
tion of WHIM-associated C-tail–truncated CXCR4 mutants (6, 22) 
is likely due to the removal of critical C-tail phospho-acceptor sites 
(5, 8, 23, 24). Supporting this assumption, β-arrestin2 overexpres-
sion, which largely exceeds the endogenous levels (Supplemental 
Figure 1B) and is known to overcome the need for GRK-dependent 
GPCR phosphorylation (25), did not promote the internalization 
of the WHIM-associated CXCR41013 receptor (Figure 3C), although 
it partly restored that of wild-type CXCR4 in patient-derived cells 
(Figure 3A). Collectively, these results led us to postulate that in 
WHIMWT cells a change in a gene product, such as GRK, that con-
trols the agonist-promoted recruitment of β-arrestin2 to CXCR4 
might account for the impaired receptor endocytosis.
CXCR4 internalization and desensitization are selectively regulated by 
GRK3. Recent works have revealed some specialization of the dif-
ferent GRKs in the regulation of GPCR signaling (26, 27), opening 
the possibility that this might be the case regarding the attenua-
tion of CXCR4. In WHIMWT fibroblasts, similarly to control cells, 
expression of GRK2, -5, or -6 had no or only a moderate effect on 
CXCL12-induced internalization of CXCR4 (Figure 4A). Inter-
estingly, GRK3 expression was highly effective in restoring nor-
mal CXCR4 endocytosis in fibroblasts from both patients (Fig-
ure 4, A and B). In contrast, GRK3 expression did not normalize 
the internalization of the C-tail–truncated CXCR41013 receptor 
ectopically expressed in control or P3 fibroblasts (Figure 4B). An 
explanation for this observation is the removal of putative target 
sites for GRK3-mediated phosphorylation (Ser338/Ser339 and 
Ser341/Thr342 couples and Ser344) in the CXCR41013 receptor. 
These results strongly suggest that CXCR4 and GRK3 specifically 
interact so that receptor internalization can take place, thus open-
ing the possibility that the capacity of exogenous GRK3 to restore 
internalization of CXCR4 in patient fibroblasts is related to inter-
actions of the kinase with the receptor.
By knocking down GRK3 mRNAs in control fibroblasts, we 
further investigated the apparent dependency of CXCR4 inter-
nalization upon GRK3 activity. In parallel, we also silenced GRK2 
mRNAs, as this kinase is closely related to GRK3 (28) and is found 
here to regulate significantly, albeit modestly, agonist-induced 
CXCR4 internalization in control cells (Figure 4A). Quantitative 
PCR and IB analyses revealed that siRNA duplexes efficiently and 
specifically depleted expression of each targeted GRK by more 
than 75% as compared with the scrambled control (SCR) siRNA 
(Figure 4C). As shown in Figure 4D, silencing of GRK3 mRNAs led 
to a marked inhibition of CXCR4 internalization upon CXCL12 
exposure, whereas suppression of GRK2 expression did not 
affect this process. Taken together, our results highlight a previ-
ously unappreciated specialization of GRK3 in the regulation of 
CXCR4 internalization. We next determined whether, by regulat-
ing CXCR4 internalization, GRK3 also contributes to receptor 
desensitization. In WHIMWT fibroblasts, only GRK3 expression 
was able to restore a normal CXCR4-dependent G protein activa-
tion following CXCL12 stimulation (Figure 4E). Collectively, these 
Figure 3
β-arrestin–mediated internalization of CXCR4. (A and B) CXCR4-
transduced fibroblasts from healthy, P3, and P4 subjects were nucleo-
porated with 5 μg pN1-EGFP (vector), pβ-arrestin1–EGFP (β-arr1), or 
pβ-arrestin2–EGFP (β-arr2) and treated 15 h after transfection with 
200 nM CXCL12 (left panels). Transfection rates >60% were obtained 
in all cell types as evaluated by flow cytometry. Results are expressed 
as percentage of CXCR4 expression (100% corresponding to CXCR4 
expression at the surface of GFP+-gated cells incubated in medium 
alone). Probing of protein extracts with an anti–β-arrestin1 or –β-arres-
tin2 Ab revealed proteins of expected molecular mass (~47 and ~46 
kDa for β-arrestin1 and -2, respectively) in each sample (right panels). 
LDH (~35 kDa) was used as a loading control. (C) Membrane expres-
sion levels of CXCR4WT or CXCR41013 upon CXCL12 stimulation in 
CTRL#1 fibroblasts nucleoporated with 5 μg pN1-EGFP (vector) or 
pβ-arrestin2–EGFP. After transduction, CXCR4WT and CXCR41013 
receptors were expressed at similar levels at the surface of unstimu-
lated cells (data not shown). Results are means ± SD of >3 indepen-
dent experiments (A–C) or are representative out of >3 independent 
determinations (A and B, right panels). *P < 0.05; **P < 0.005 com-
pared with fibroblasts transfected with vector.
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results reveal a pivotal role for GRK3 in the regulation of CXCR4 
desensitization and internalization and further point to GRK3 as 
a candidate responsible for the impaired CXCR4 attenuation in 
WHIMWT cells. Supporting this assumption, GRK3-silenced con-
trol cells displayed an impaired CXCR4 endocytosis upon CXCL12 
exposure, as do WHIMWT cells. Conversely, GRK3 expression in 
WHIMWT cells normalized CXCR4 desensitization and endocyto-
sis. These observations argue in favor of a quantitative or qualita-
tive change in GRK3 in WHIMWT cells.
Differential steady-state levels of GRK3 products in WHIMWT leuko-
cytes. To investigate whether WHIMWT cells display a quantita-
tive change in GRK3 proteins, we assessed by IB the levels of 
Figure 4
GRK3-mediated internalization and desensitization of CXCR4. (A) Aforementioned fibroblasts from CTRL#1, P3, and P4 subjects expressing 
CXCR4 were nucleoporated with 5 μg of either pcDNA1 (vector) or GRK2, -3, -5, or -6 construct and treated 15 h after transfection with 200 nM 
CXCL12. We always controlled the efficiency of GRK overexpression by IB (Supplemental Figure 2C). (B) CXCL12-promoted internalization of 
CXCR4WT or CXCR41013 in fibroblasts from CTRL#1 and P3 nucleoporated with 5 μg of either pcDNA1 (vector) or plasmid encoding GRK3 cDNA. 
(C) Expression of GRK products in fibroblasts from healthy subjects nucleoporated with 5 μg SCR, GRK2, or GRK3 siRNAs. Three days after 
transfection, GRK mRNA levels were assessed by quantitative PCR (left and middle panels) and normalized to those of IDUA. IB of proteins from 
whole-cell lysates either with an anti-GRK2/3 mAb (data not shown) or an anti-GRK2 or anti-GRK3 Ab (right panel) revealed proteins of expected 
molecular mass (~80 kDa). GRK2 or -3 siRNAs had no effect on expression levels of endogenous GRK6 or β-arrestin2 (molecular mass ~65 and 
~46 kDa, respectively), as detected using selective Abs (Supplemental Figures 1 and 2). (D) Cell surface expression levels of CXCR4 in GRK2 
or -3 siRNA-transfected fibroblasts treated with CXCL12. GRK2 or -3 siRNAs had no effect on expression levels of CXCR4 at the membrane 
of unstimulated cells (data not shown). (E) CXCR4-transduced fibroblasts from CTRL#1, P3, and P4 individuals were nucleoporated with 5 μg 
of pcDNA1 (vector) or GRK2 or -3 construct and tested for CXCL12-triggered actin polymerization. Results are means ± SD of 3–6 indepen-
dent experiments (A and B; C, left and middle panels; and D and E) or are representative of >5 independent determinations (C, right panel). 
*P < 0.05; #P < 0.005 compared with fibroblasts transfected with vector (A and B) or SCR siRNAs (C and D).
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GRK2, -3, -5, and -6 in whole-cell lysates from primary leukocytes 
isolated from P3, P4, and healthy subjects including members of 
P4’s family (Figure 5A). No change in GRK3 levels was detected 
in leukocytes from P4 (Figure 5A). In contrast, the levels of GRK3 
in leukocytes from P3 were profoundly reduced compared with 
controls, whereas the steady-state levels of GRK2, -5, and -6 were 
normal as detected with Abs that react specifically with GRK2 
or -6 or the GRK5/6 pair (Figure 5B and Supplemental Figure 2, 
A and C). The decrease in GRK3 protein levels, also confirmed in 
P3 fibroblasts (Figure 6A), was accessed using a mAb that reacts 
with GRK2 and -3 proteins (>60% reduction as compared with 
control cells) (Supplemental Figure 2, C and D), both readily dis-
tinguished as a doublet (Supplemental Figure 2B), or an Ab that 
selectively recognizes GRK3 proteins (~90% reduction as compared 
with controls) (Supplemental Figure 2, A and D).
To determine whether the decrease in GRK3 proteins identi-
fied in P3 leukocytes was mirrored at the mRNA level, total RNA 
was isolated from P3 and control leukocytes, and the steady-state 
levels of GRK3 transcripts were assessed by PCR analysis. Using 
semiquantitative PCR, we found that the band corresponding to 
the amplified GRK3 cDNA product was barely detectable in P3 leu-
kocytes as compared with control cells, suggesting a drastic reduc-
tion of GRK3 transcript amounts in P3 cells (Figure 5C). In con-
trast, the steady-state levels of GRK2, -5, and -6 mRNAs were similar 
in P3 and control leukocytes. Amounts of GRK transcripts in P4 
leukocytes were not different from those detected in control cells 
as shown by semiquantitative PCR analysis (Figure 5D). We then 
set up real-time PCR analysis to quantify levels of GRK3 mRNAs in 
P3 leukocytes as compared with those detected in 5 independent 
healthy individuals, among which 3 are family members (Figure 
5C). The steady-state levels of GRK3 transcripts in control indi-
viduals displayed over a large range (Figure 5C). This observation 
is probably the consequence of an inter-individual variability that 
is also revealed by a similar comparative analysis performed in leu-
kocytes from P4 and healthy members of P4’s family (Supplemen-
tal Figure 3). However, GRK3 mRNA levels were out of range in P3 
leukocytes (Figure 5C) and only minute amounts were detectable 
in accordance with the semiquantitative PCR analysis. We also 
confirmed by real-time PCR that the steady-state levels of other 
GRK mRNAs were quantitatively unaffected in P3 cells (data not 
shown). Thus, these results indicate that the marked alteration 
in GRK3 protein levels in P3 leukocytes correlates with a selective 
decrease at the mRNA level. Additionally, our findings strongly 
suggest that the decreased steady-state level of GRK3 proteins in 
P3 leukocytes results from an alteration in a (post-)transcriptional 
mechanism rather than in protein stability.
Defective GRK3 mRNA expression in P3 fibroblasts. RNA stability 
studies were set up in patient-derived fibroblasts, which constitute 
a more homogenous cell system than leukocytes. As shown in Fig-
ure 6A, fibroblasts from P3 displayed a selective reduction (>75%) in 
GRK3 protein levels relative to controls, as did leukocytes (see Figure 
5B). We also confirmed that the steady-state levels of GRK2, -3, -5, 
and -6 proteins were unaffected in fibroblasts and EBV-B cells (data 
not shown) from P4. Of note, exogenously expressed GRK3, which 
was found to restore CXCR4 internalization and desensitization in 
P3 and P4 fibroblasts (Figure 4, A, B, and E), reached similar lev-
els among control and patient fibroblasts that largely exceeded the 
endogenous ones (Supplemental Figure 2C). Whereas the amounts 
Figure 5
Reduced levels of GRK3 products in P3 leukocytes. (A and B) The steady-state levels of GRK proteins in leukocytes from P4 (A) and P3 (B) 
were compared with those obtained in leukocytes from family members and a healthy individual (CTRL#1), respectively. Total protein extracts 
(20 μg/lane) were analyzed by IB using an anti-GRK2/3, -GRK2, -GRK3, -GRK5/6, or -GRK6 Ab. (C and D) The steady-state levels of GRK 
transcripts in leukocytes from P3 (C) and P4 (D) were compared by PCR with those obtained in leukocytes from family members and healthy 
individuals (CTRL#2–5). Semi-quantitative (C, middle panel, and D) and real-time (C, right panel) PCRs were performed using specific prim-
ers flanking the full GRK ORFs or within them, respectively. One band corresponding to amplified LDH (~1.3 kb), GRK2 (~2.2 kb), GRK3 (~2.1 
kb), GRK5 (~1.8 kb), or GRK6 (~1.8 kb) cDNA products was detected in each sample by semi-quantitative PCR. The thin horizontal lines in the 
gel indicate that the lanes were run on the same gel but were noncontiguous. Results are from 1 representative experiment of 3 (A–D) or are 
means ± SD of 3 independent determinations performed in triplicate (C, right panel). **P < 0.005 compared with III-1 individual.
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of GRK mRNAs were unaltered in P4 fibroblasts compared with con-
trol ones, we observed a drastic decrease (>85%) of GRK3 transcripts 
in P3 fibroblasts (Figure 6, B and C). A single GRK3 cDNA product 
was amplified by PCR using specific primers flanking the full ORF 
in patient-derived leukocytes (Figure 5) and fibroblasts (Figure 6). 
Double-strand sequencing of amplified products revealed no muta-
tion either in the GRK3 ORF or in those of GRK2, -5, and -6.
We speculated that the reduced level of GRK3 transcripts in P3 
cells might result from 2 mechanisms not mutually exclusive: inef-
ficient mRNA synthesis or increased mRNA degradation. A time 
course of GRK3 mRNA stability was performed in the presence of 
the transcriptional inhibitor actinomycin D (ActD) in fibroblasts 
from P3, P4, and 2 healthy subjects. The estimated half-life (>3 h) 
of a stable mRNA species, lactate dehydrogenase (LDH), was found to 
be similar in all cell types (Figure 7A). GRK3 mRNAs were found to 
have a short half-life (~1 h), and their stabilities were in the same 
range in both control- and patient-derived fibroblasts (Figure 7B). 
These findings rule out the possibility that an impaired mRNA 
stability accounts for the decrease of GRK3 transcripts in P3 fibro-
blasts, and argue in favor of an altered GRK3 transcription. We 
thus set up pulse/chase ActD experiments and determined that a 
4-hour treatment with ActD was sufficient to deplete GRK3 
mRNAs (<15% of the pretreatment levels) in all cell types (Figure 
7C). After 4 h of ActD chase, the level of GRK3 mRNAs was fully 
recovered in P4 and control fibroblasts, whereas it only reached 
50% of the pretreatment levels in P3 fibroblasts. Taken together, 
these results strongly suggest that the decreased level of GRK3 pro-
teins in P3 cells primarily results from an impaired GRK3 mRNA 
synthesis and ultimately leads to defective CXCR4 attenuation.
GRK3 negatively regulates CXCL12-promoted cell migration. We hypoth-
esized that the enhanced CXCL12-promoted chemotaxis of P3 cells, 
previously proposed to rely on the refractoriness of CXCR4 to be 
both desensitized and internalized (6), could be normalized upon 
GRK3 expression. To address this issue, leukocytes from healthy and 
P3 subjects were transfected either with a control vector or a plas-
mid encoding GRK3 cDNA (Supplemental Figure 2D). Confirming 
our previous findings, CD4+ T cells from P3 displayed a stronger 
chemotactic response toward a CXCL12 gradient relative to controls 
Figure 6
Differential steady-state levels of GRK3 products in WHIMWT fibroblasts. Analyses of GRK protein and mRNA levels in fibroblasts from P3, P4, 
and 2 independent healthy subjects (CTRL#1 and #2) were performed by IB (A), semi-quantitative (B), and real-time (C) PCRs as described in 
the legend of Figure 5. Results are from 1 representative experiment of 6 (A and B) or are means ± SD of 3 independent determinations per-
formed in triplicate (C). **P < 0.005 compared with CTRL#1.
Figure 7
Expression and stability of GRK3 mRNAs in WHIMWT fibroblasts. 
Fibroblasts from P3, P4, and healthy subjects were incubated with 10 
μg/ml ActD (treatment) for the indicated times (A and B) or for 4 h 
and further cultured for 4 h in the absence of ActD (chase) (C). At the 
indicated times, total RNA was extracted and semi-quantitative PCRs 
were performed using specific primers flanking the full LDH or GRK3 
ORF. Amplified cDNA products were run on 1% agarose gels, detected 
by ethidium bromide staining, and quantified by computed-assisted 
densitometry using the ImageJ 1.34 software (NIH). Results are from 
1 representative experiment out of 3 (A and B) or are means ± SD of 3 
independent determinations (C) and indicate the amount of mRNAs that 
remained after incubation with ActD (A and B) or that accumulated in 
the course of ActD chase (C). Transcript levels in fibroblasts incubated 
in medium alone were set as 100%. Kinetics of LDH mRNA appearance 
were comparable in all cell types (data not shown). *P < 0.05.
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(Figure 8A). We found that GRK3 expression significantly reduced 
CXCL12-promoted migration of control T cells (30%–40% inhibi-
tion as compared to cells transfected with vector), suggesting that 
GRK3 plays a negative role in the regulation of this process. Consis-
tent with this, GRK3 expression in leukocytes from P3 permitted the 
restoration of normal CXCL12-induced chemotactic responses.
By knocking down GRK3 mRNAs in leukocytes from healthy 
subjects, we further investigated the dependency of CXCR4-medi-
ated cell migration upon GRK3 activity. As determined by real-
time PCR, GRK3 siRNA duplexes efficiently reduced the levels 
of GRK3 transcripts by more than 60% (Figure 8B). Addition of 
CXCL12 resulted in a dose-dependent chemotaxis of SCR siRNA-
transfected CD4+ T cells (Figure 8B). Supporting a negative role 
for GRK3 in CXCL12-promoted chemotaxis, we found that the 
sensitivity of GRK3-silenced CD4+ T cells to CXCL12 was strongly 
increased. This process was associated with a decrease in the maxi-
mal effective concentration of CXCL12.
Discussion
Investigation of the molecular basis of CXCR4 dysfunctions in 2 
patients suffering from the genetic form of WHIM syndrome not 
associated with CXCR4 mutation reveals a surprising dependency 
of CXCR4 functioning upon GRK3 activity. For instance, our 
data demonstrate a pivotal role for GRK3 in CXCL12-promoted 
desensitization and internalization of CXCR4. They also point 
to alterations in GRK3 activity in patient-derived cells that likely 
account for the CXCR4 dysfunctions. Several observations sup-
port this possibility. First, control cells knocked down for GRK3 
mRNAs displayed impaired CXCR4 attenuation and enhanced 
chemotaxis in response to CXCL12, as do WHIMWT cells. Second, 
GRK3 expression in WHIMWT cells restored the capacity of CXCR4 
to be desensitized and internalized in response to CXCL12. Finally, 
and perhaps most importantly, we revealed in cells derived from 
one patient a selective decrease in GRK3 products that likely arises 
from impaired mRNA synthesis and the correction of which led to 
a normalized chemotaxis.
CXCL12-promoted desensitization and internalization of CXCR4 
is thought to be dependent upon binding of β-arrestin to the GRK-
phosphorylated receptor (8, 9, 18). Our data challenge the possi-
bility that β-arrestin1 or β-arrestin2 per se could be impaired in 
patient-derived cells and rather point to GRK3 activity as the lim-
iting step. In WHIMWT and control cells, the steady-state levels of 
β-arrestin products were found to be similar (Figure 3, A and B, and 
Supplemental Figure 1C), as well as the internalization of chemo-
kine receptors other than CXCR4 (Figure 2C). These results suggest 
that the endocytic pathway downstream of β-arrestin recruitment 
to the receptors is preserved in WHIMWT cells. In line with this, 
ectopically expressed β-arrestins, and most particularly β-arres-
tin2, had the ability to modulate CXCR4 internalization (Figure 3). 
However, this effect was partial, whereas for exogenous GRK3, it 
was total (Figure 4, A and B). Indeed, GRK3 expression overcame 
the resistance of CXCR4 to internalize in response to CXCL12 in 
patient-derived cells, including those from P4, which displayed nor-
mal steady-state levels of GRK3 products (Figures 5 and 6). Che-
mokine receptor internalization is facilitated by GRK expression, as 
previously reported for CXCR4 upon transfection of GRK2 cDNA 
in HEK 293T cells (8, 9) and here in primary fibroblasts (Figure 4A). 
The fact that GRK2 silencing did not modulate CXCL12-induced 
internalization of CXCR4 in control fibroblasts (Figure 4D) sug-
gests a minor contribution of this kinase to this process and makes 
it likely that GRK3 activity is sufficient for receptor phosphorylation 
in those cells. Consistent with this, GRK3 silencing impaired CXCR4 
internalization in control cells, indicating that neither endogenous 
GRK2 nor GRK5 or -6 substituted for the loss of GRK3.
Endogenous GRK3 has been shown to mediate the agonist-depen-
dent phosphorylation and internalization of other GPCRs, such as 
Figure 8
Consequences of GRK3 expression or knock-down on CXCL12-pro-
moted chemotaxis. (A) Leukocytes from healthy (CTRL#1) and P3 
subjects were nucleoporated with 5 μg of either pcDNA1 (vector) or 
plasmid encoding GRK3 cDNA and assayed 15 h after transfection 
for chemotaxis in response to CXCL12. (B) IL-2–expanded leukocytes 
that contained >95% CD25+ blasted T cells, as evaluated by flow 
cytometry, from independent healthy individuals were nucleoporated 
with 5 μg SCR or GRK3 siRNAs. Two days after transfection, leuko-
cytes were tested for their ability to migrate in response to CXCL12 
(right panel). Transmigrated cells recovered in the lower chamber were 
stained with mAbs specific for CD3 and CD4 antigens and counted by 
flow cytometry. Results, expressed as a percentage of input CD4+-
gated T cells that migrated to the lower chamber, are representative 
of those obtained in CD8+-gated T cells. GRK3 transcript levels were 
evaluated by quantitative PCR and normalized to those of IDUA (B, 
left panel). Inhibition or increase of GRK3 expression had no effect on 
cell surface expression of CXCR4. Results are from 1 representative 
determination of 2 performed in triplicate (A) or are means ± SD of 3 
independent determinations performed in duplicate (B, right panel) or 
in triplicate (B, left panel). *P < 0.05; **P < 0.005 compared with leuko-
cytes transfected with vector or SCR siRNAs.
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angiotensin II and V2 vasopressin receptors (26, 27). Analyses of 
GRK3-deficient mice reveal a physiological role for Grk3 in the reg-
ulation of olfactory, M2/M3 muscarinic and kappa opioid receptor 
activities (29–31). However, whether Grk3 deficiency affects GPCRs 
also involved in the immune system homeostasis has not been inves-
tigated. Here, by the use of alternative approaches (overexpression 
combined with siRNA methods), we uncover a selective role for 
GRK3 in the regulation of CXCL12-promoted attenuation of CXCR4 
that likely implicates agonist-induced C-tail phosphorylation and 
the subsequent recruitment of β-arrestin2 to phosphorylated recep-
tors. In line with this, the failure of either β-arrestin2 or GRK3 over-
expression to correct impaired CXCL12-induced internalization of 
the WHIM-associated CXCR41013 receptor was consistent with the 
removal of phosphorylation sites in the C-tail truncated receptor 
that prevents the physical interaction of the kinase with the receptor 
(Figure 3C and Figure 4B). GRK3 and the structurally related GRK2 
have the reported ability to interact with the activated GTP-bound 
form of some Gα proteins, notably Gαq and Gα11, and to acceler-
ate their intrinsic GTPase activity (reviewed in ref. 28). CXCR4 is 
thought to generally activate Gαi proteins, but it also displays the 
capacity to couple to Gα12/13 (32, 33) or Gαq proteins (34, 35). 
This opens the possibility that the binding of GRK3 to G proteins 
might contribute in some conditions to CXCR4 desensitization in a 
phosphorylation and/or β-arrestin–independent manner.
The enhanced CXCL12-promoted chemotaxis displayed by P3 T 
cells (Figure 8A) likely arises from the drastic diminution of GRK3 
products that characterizes P3-derived cells (Figures 5 and 6). This 
assumption is supported by the fact that GRK3 expression in P3 T 
cells was sufficient to correct altered CXCL12-induced chemotaxis, 
and conversely that GRK3 silencing in control T cells results in a 
WHIM-like phenotype (Figure 8). The mechanism by which GRK3 
levels fine-tune CXCL12-promoted cell migration might involve the 
pivotal role of GRK3 in promoting β-arrestin2–mediated CXCR4 
desensitization. In addition to desensitization, recent studies sug-
gest that β-arrestin2 contributes to chemotaxis by virtue of its abil-
ity to serve as scaffold for signaling molecules, including members 
of the MAPK family (4). β-arrestin2 was shown to positively modu-
late CXCR4-mediated chemotaxis of mouse and human cells (10, 
36). Thus, changes in GRK3 activity in WHIMWT cells may indirectly 
modulate the ability of β-arrestin2 to scaffold CXCR4-mediated 
signaling pathways. Recent findings indicate that different GRKs 
may set in motion distinct functions of GPCR-bound β-arrestin 
(26, 27, 37, 38), opening the possibility that a specialization of 
GRKs also takes place in the regulation of β-arrestin2–dependent 
CXCR4 signaling. For instance, studies from Grk6-deficient mice 
suggest a positive contribution of this kinase to the CXCL12-
induced chemotaxis of T cells, whereas Grk6 appears to play an 
opposite role in neutrophils (10, 15). These results, if extended to 
the regulation of CXCR4-mediated signaling in human cells, would 
open the possibility that GRK6 and GRK3 differentially regulate 
CXCR4 activities. In WHIMWT cells, our results indicate that GRK6 
is not dysregulated and highlight a role for GRK3 dysfunctions per 
se in the enhanced CXCL12-promoted chemotaxis.
We reveal that functional CXCR4-related defaults in P3 cells 
result from a dramatic decrease in GRK3 proteins, likely due to 
an impairment in mRNA expression but not stability (Figure 7). 
The relatively short half-life of GRK3 mRNA species is consistent 
with the reported tight regulation of the GRK3 promoter by vari-
ous inducers, including κ-opioid agonists, corticotropin-releasing 
factor, epinephrine, or the cytokine GM-CSF (39–43). Collectively, 
these observations suggest that the defective GRK3 mRNA expres-
sion in P3 cells arises from an impaired synthesis, either directly 
due to a polymorphism in transcriptional regulatory regions or 
indirectly due to the altered expression of a transcription factor 
that modulates GRK3 expression. Several SNPs were identified 
in the putative promoter region of GRK3, which may affect the 
regulation of gene expression, and were associated with bipolar 
disorder in families of northern European Caucasian ancestry (44, 
45). We did not identify any specific SNP in the minimal putative 
promoter region of GRK3 in P3 cells. Therefore, cloning and func-
tional characterization of the whole GRK3 transcriptional regu-
latory sequence may help to define mechanisms by which GRK3 
expression is fine-tuned in P3 cells.
The molecular mechanism accounting for the impaired CXCR4 
attenuation in P4 cells is predicted to arise upstream β-arrestin2 
recruitment to CXCR4 and coupling of the receptor to the endo-
cytic pathway. Several aspects of our findings make it more likely 
that the defect occurs through a direct dysregulation of GRK3 sub-
cellular localization and/or activity rather than a GRK3-unrelated 
process of receptor downregulation. In particular, the resistance 
of the CXCR41013 receptor to internalize upon CXCL12 stimula-
tion, even in the presence of large amounts of GRK3 (Figure 4B), 
strongly suggests that GRK3 physically interacts with the C-tail 
of CXCR4. So, the selective effect of overexpressed GRK3 in cor-
recting impaired CXCR4 internalization in P4 cells (Figure 4A) is 
believed to result from the restoration of specific interactions of 
the kinase with the receptor and thus to overcome a deficiency in 
GRK3 activity. The normal production, stability, and translation of 
GRK3 mRNAs in P4 cells (Figures 5–7), combined with the absence 
of mutation in the GRK3 ORF, challenge the possibility of intrinsic 
changes in GRK3 proteins. Additionally, these observations sug-
gest that GRK3-related CXCR4 dysfunctions arise from different 
genetic anomalies in P3 and P4 subjects with full clinical form of 
WHIM syndrome. Based on recent advances in our knowledge of 
the GRK interactome (reviewed in ref. 28), we speculate that altera-
tion in one of GRK’s binding partners may lead to impaired GRK3 
localization and/or activity in P4 cells. A fuller understanding of 
the functioning of GRK3 should provide insight into the biology 
of the CXCL12/CXCR4 axis and likely into the aberrant leukocyte 
trafficking in the course of WHIM syndrome.
Methods
Antibodies, reagents, and cells. Immunostainings were performed using the 
FITC-conjugated anti-human CD3 mAb (clone SK7), the PE-conjugated 
anti-human mAbs specific for CCR5 (clone 2D7), CCR7 (clone 3D12), 
CXCR2 (clone 48311.211), CXCR4 (clone 12G5), and CXCR5 (clone 
51505.111) as well as the APC-conjugated anti-human CD4 (clone RPA-
T4) mAb. All mAbs were purchased from BD Biosciences. The binding 
of the mouse anti-human RDC1/CXCR7 mAb (clone 9C4, provided by 
M. Thelen, Institute for Research in Biomedicine, Bellinzona, Switzerland) 
was detected as described (16). Unless specified, MIP-1β/CCL4, SDF-1/
CXCL12, and RANTES/CCL5 and IL-8/CXCL8 (both from R&D Systems) 
were used at 30 nM, whereas 6Ckine/CCL21 and BCA-1/CXCL13 (R&D 
Systems) were used at 60 nM and 100 nM, respectively. PMA (Sigma-
Aldrich) was used at 200 nM.
PBLs were isolated from heparin-treated blood samples of healthy indi-
viduals and WHIMWT patients P3 and P4 as previously described (6) and cul-
tured in RPMI 1640 medium supplemented with 10% FCS, 10 mM HEPES, 
penicillin (100 U/ml), and streptomycin (100 μg/ml) (complete RPMI 
medium). When required, PBLs from healthy subjects were either nega-
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tively enriched for CD4+ T cells as previously described (46) or incubated 
for 24 h with phytohemagglutinin (1 μg/ml; Sigma-Aldrich) followed by 
6 days with IL-2 (20 ng/ml; PeproTech) for blasting. The A0.01 T cell (from 
H.T. He, Centre d’Immunologie de Luminy, Marseille, France) and Jurkat 
cell (ATCC) lines were maintained in complete RPMI medium. The CHO 
K1 cell line (ATCC) was cultured in complete HAM F-12 medium. Dermal 
fibroblasts, isolated and expanded from healthy and WHIMWT skin biop-
sies, were maintained in complete DMEM. EBV-transformed B cell lines 
derived from healthy individuals and P4 were cultured in complete RPMI 
medium supplemented with 50 μM 2-mercaptoethanol. The marked B cell 
lymphopenia affecting P3 did not permit us to generate a B cell line. This 
study was approved by the Direction Médicale et Santé Publique, Institut 
Pasteur, and all subjects gave informed consent for this investigation.
Transfection and functional assays. The human SMARTpool SCR (siCON-
TROL non-targeting#1), GRK2, and GRK3 siRNA duplexes (Dharmacon); 
the pN1-EGFP, pβ-arrestin1–EGFP, and pβ-arrestin2–EGFP plasmids (pro-
vided by S. Marullo, Institut Cochin, Paris, France); the pcDNA1 encoding 
bovine GRK2, -3, or -5 or human GRK6 cDNA (gift from M. Oppermann, 
University of Göttingen, Germany); the pcDNA3 encoding human CXCR2 
cDNA and the pSRαpuro-CCR7 and -CXCR2 plasmids (gift from B. Moser, 
Theodor-Kocher Institute, Bern, Switzerland); and the lentiviral-derived 
pTRIP vectors (gift from P. Charneau, Unité de Virologie Moléculaire et 
de Vectorologie, Institut Pasteur, Paris, France) encoding human CCR5, 
CXCR4, CXCR41013, or CXCR7 cDNA were transfected as specified in the leg-
ends to Figures 1–4 and Figure 8. Transient expression was achieved using 
amaxa Nucleofector technology, and stable expression was obtained using 
a lentiviral-based strategy as previously described (6). Receptor internaliza-
tion, actin polymerization, and chemotaxis assays were performed as previ-
ously described (6, 46). Statistical analyses consisted of unpaired 2-tailed 
Student t tests and were conducted with the Prism software (GraphPad).
RT-PCR analysis. Total cellular RNA was extracted using the RNeasy kit 
(QIAGEN Sciences) and reverse transcribed (Superscript II, BD Biosciences 
Clontech) by extension of oligo(dT) priming using a template-switch 
primer 5′-AAGCAGTGGTATCAACGCAGAGTAC[T]20VN-3′ (47). Ampli-
fication of oligo(dT)-primed cDNAs was performed by PCR (Advantage II 
pol; BD Biosciences — Clontech) (40 cycles: 95°C 30 s, 68°C 3 min) using 
forward 5′-GGTTCCAAGTCCAATATGGCAA-3′ and reverse 5′-ACTAG-
GCATGTTCAGTGAAGGAGC-3′ primers for LDH, forward 5′-CAAGAT-
GGCGGACCTGGA-3′ and reverse 5′-GGGTTGGTGCAGCAGGA-3′ 
primers for GRK2, forward 5′-CCGCCAAAGCTCGCCAAC-3′ and reverse 
5′-ATCAGATGCCTCATCCTCGTTCAC-3′ primers for GRK3, forward 
5′-GCTCCGTTGCTGACCGC-3′ and reverse 5′-CACTGTGGACTTGGAG-
GC-3′ primers for GRK5, and forward 5′-GCCACAGCCCATGGAGC-3′ 
and reverse 5′-AGCTGCTACCGCCAACTGCT-3′ primers for GRK6. For 
RNA synthesis and stability assays, cells were treated with 10 μg/ml ActD 
(Sigma-Aldrich) for 0–4 h before RNA isolation. mRNA half-lives were 
determined by fitting exponential decay curves to experimental data points. 
Primer pairs for quantitative RT-PCR were retrieved on the PrimerBank 
Web site (http://pga.mgh.harvard.edu/primerbank/) (48). PCR reactions 
were performed with SYBR Green (Applied Biosystems) detection using 
forward 5′-CTCGGGCCACTTCACTGAC-3′ and reverse 5′-CAGTCCG-
TACCTACCGATGTAT-3′ primers for α–l-iduronidase (IDUA), forward 
5′-ACTTCAGCGTGCATCGCAT-3′ and reverse 5′-GCTTTTTGTCCAG-
GCACTTCAT-3′ primers for GRK2, forward 5′-AGCTGTAGAACACGTA-
CAAAGTC-3′ and reverse 5′-ATGTCACCTCGAAGGCTTTCA-3′ primers 
for GRK3, and forward 5′-TAGCGAACACGGTGCTACTC-3′ and reverse 
5′-GCTGATGTGAGGGAACTGGA-3′ primers for GRK6. We used the ABI 
7300 Sequence Detection System (Applied Biosystems) with the following 
amplification scheme: 50°C 2 min, 95°C 10 min and 40 cycles: 95°C 15 s, 
60°C 30 s, 68°C 40 s. The dissociation curve method was applied accord-
ing to the manufacturer’s protocol (60°C to 95°C) to ensure the presence 
of a single specific PCR product. Analysis was performed with the standard 
curve method, and results were expressed as GRK/IDUA ratios.
IB analysis. Equivalent amounts of proteins (30 μg/lane unless specified) 
were separated by SDS-PAGE on 4%–12% Tris-glycine polyacrylamide gels 
(Invitrogen), transferred to PVDF membrane and probed with the follow-
ing monoclonal or polyclonal Abs: sheep anti-human LDH (Biodesign), 
rabbit anti-human β-arrestin1 (clone E246; Epitomics), rabbit anti-serum 
to β-arrestin2 (a gift from R.J. Lefkowitz, Howard Hughes Medical Insti-
tute, Durham, North Carolina, USA), rabbit anti-human GRK2 or -6, 
goat anti-human GRK3 (all from Santa Cruz Biotechnology Inc.), mouse 
anti-rat GRK2/3 (clone C5/1) or anti-bovine GRK5/6 (clone A16/17, both 
provided by M. Oppermann) Abs. Peroxidase-conjugated anti-mouse, anti-
rabbit (both from Amersham Biosciences) and anti-goat (Vector Laborato-
ries) Abs were used to detect bound primary Abs by enhanced chemilumi-
nescence. IB quantitation was done using an LAS-1000 CCD camera with 
Image Gauge 3.4 software (Fuji Photo Film Co.).
Immunoprecipitation assay. Cells (5 × 106 to 10 × 106) transduced or not 
with CXCR4WT or CXCR41013 were serum-starved overnight and lysed in 
0.2 ml ice-cold lysis buffer (LB; 30 mM HEPES, 100 mM KCl, 20 mM NaCl, 
2 mM MgCl2, 5% glycerol, 2% heptanetriol [Fluka], 0.5% laurylmaltoside, 
5 mM GDP, 1 mM microcystin [Sigma-Aldrich], 1 mM orthovanadate and 
protease inhibitors [Roche Diagnostics]) for 30 min at 4°C. Precleared 
lysates were incubated overnight at 4°C with the 12G5 anti-CXCR4 mAb 
precoated on γ-bind sepharose beads (Amersham). After 3 washes in LB, 
immunoprecipitated receptors were eluted in SDS-PAGE sample buffer (25 
mM Tris-HCl pH 6.8, 5% glycerol, 1.5% SDS, 0.1% bromophenol blue) for 
45 min at 37°C and detected by IB analysis using the SZ1567 anti-CXCR4 
rabbit polyclonal Ab (provided by M. Thelen).
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